Biostatistiker (m/w)

Biostatistiker (m/w)

20181127_BiostatistikerDie Staburo GmbH ist ein Münchner Biostatistikunternehmen, das auf statistische Beratung und Programmierung im Umfeld von klinischen Studien spezialisiert ist. Aufbauend auf unseren 6 Säulen (Klinische Statistik, Translationale Medizin & Biomarker, Pharmakokinetik/-dynamik, Nutzenbewertung, Nichtklinische Statistik und Statistische Programmierung mit CDISC) erarbeiten wir in Projektteams maßgeschneiderte Lösungen.
Unsere Kunden sind renommierte Pharmafirmen (7 der Top 20), CROs und Biotechunternehmen, mit denen wir flexibel und gerne auch vor Ort zusammenarbeiten.

Zur Erweiterung unseres Teams suchen wir zum nächstmöglichen Zeitpunkt zur Festanstellung einen

Biostatistiker (m/w)

 
Ihre Aufgabengebiete:
  • Auswertung klinischer Studien der Phasen I – IV und Präsentation der Ergebnisse
  • Statistische Programmierung (SAS mit SDTM und ADaM; R)
  • Programmvalidierung von klinischen Studien
  • Unterstützung bei der Studien- und Patientenfallzahlplanung
  • Erstellung der SAPs und der Studiendesigns
  • Ansprechpartner für unsere Mitarbeiter und Kunden
Ihr Profil:
  • Erfolgreich abgeschlossenes Studium im Bereich Statistik, Mathematik, oder eine vergleichbare Ausbildung
  • Sehr gutes methodisches Wissen im Bereich klinische Statistik
  • Mehr als 2 Jahre Berufserfahrung als Statistiker mit Verantwortung für klinische Studien
  • Sehr gute EDV Kenntnisse, besonders mit statistischen Analysetools (SAS, R)
  • Schnelle Auffassungsgabe und analytisches Denkvermögen
  • Teamfähigkeit und ein hohes Maß an Eigeninitiative
Was wir Ihnen bieten:

Es erwartet Sie eine abwechslungsreiche, eigenverantwortliche Tätigkeit mit sehr guten Entwicklungsmöglichkeiten. Wir legen großen Wert auf Kommunikation, flache Hierarchien, offene Unternehmenskultur und ein harmonisches Arbeitsumfeld. Unser Standort in München bietet sehr gute Arbeitsbedingungen, moderne Büroräume und eine schnelle Anbindung an den öffentlichen Nahverkehr.

Neugierig geworden?

Dann informieren Sie sich auf unserer Internetseite: www.staburo.de und werden Teil unseres stetig wachsenden Teams!
Wir freuen uns über Ihre vollständigen Bewerbungsunterlagen mit Angabe Ihrer Gehaltsvorstellung. Für eine schnelle Abwicklung des Bewerbungsprozesses bitten wir um eine E-Mail-Bewerbung an: bewerbung@staburo.de.

Hier finden Sie diese Stellenanzeige als PDF Datei.

 

Training @ Staburo: RNASeq vs. Microarrays

Training @ Staburo: RNASeq vs. Microarrays

Training @ Staburo: How to measure the abundance of mRNA, using Microarrays and Sequencing Technologies

The normal function of cells depends on accurate expression of a large number of proteins. As it is difficult to measure the number of thousands of proteins simultaneously, a pre-state of them – the so called protein coding RNAs (messenger RNAs; mRNAs) – are normally measured.
Staburo GmbH Bioinformatician Dr. Janine Roy started this talk with an introductory overview of protein synthesis, to answer the question – How is the information coded in the DNA translated to functioning proteins? Therefore, the structure of a cell with its organelles, Translation from DNA to pre-mRNA, splicing as well as the genetic code was profoundly explained.
Afterwards she moved to (DNA-)Microarrays and RNA-Sequencing.
Microarrays are used to measure the expression levels of large numbers of genes simultaneously. The composition of a Microarray and the general workflow of an experiment was shown on an example.
RNA-Sequencing uses next-generation sequencing techniques to reveal the presence and quantity of RNA. As many sequencing techniques exists, the technique of Sequencing by Synthesis was explained exemplary on a more detailed level.
The talk finished with a rigorous comparison of (dis-) advantages of (DNA-)Microarrays and RNA-Sequencing.

Data analysis, clinical biostatistics and more.

Staburo @ BIO-M Workshop: Start thinking with the end in mind: Using the right Data in Clinical Development and Market Access

Staburo @ BIO-M Workshop: Start thinking with the end in mind: Using the right Data in Clinical Development and Market Access

Staburo @ BIO-M Workshop: Start thinking with the end in mind: Using the right Data in Clinical Development and Market Access

Staburo’s Managing Director Roland Stieger attended the BioM seminar with the topic “Using the right Data in Clinical Development and Market Access” in Munich.
The main topic at this seminar was the future of Clinical Trial Designs, Real World Evidence Plus, further Market Access – study requirements and strategic insights in context of the patient related data to facilitate clinical development. Integrated, patient centered thinking may grant additional opportunities to develop better solutions faster in the clinical field.
Speakers were Dr. Ute Simon, Medical Director at the Novartis Pharma GmbH, Dr. Timm Volmer, Founder from SmartStep Healthcare & Market Access Consulting GmbH and Dr. Reiner Lehmann, Founder from DontBePatient Intelligence GmbH.

Novartis Pharma is one of the largest pharmaceutical companies. Novartis uses science-based innovation to address some of society’s most challenging healthcare issues. The talk was about the future of clinical development and the clinical trial designs.

SmartStep Healthcare & Market Access Consulting provides individualized and specialized consulting for the pharmaceutical and medical device industry, in order to achieve a rapid and effective market access for their products. Dr. Volmer’s topic was the integrated Market Access planning with questions like how to obtain advice from HTA institutions.

DontBePatient Intelligence generates Real World Insights derived from patients. Dr. Reiner Lehmann talked about how to identify and engage patients in the digital space and how to generate data to inform target population selection, trial design and choice of endpoints through patient derived information.

We thank BioM for the organisation and the speakers for their expert insights!

Data analysis, clinical biostatistics and more.

Training @ Staburo: Adaptive Enrichment Design Biostatistics Workshop

Training @ Staburo: Adaptive Enrichment Design Biostatistics Workshop

Training @ Staburo: Adaptive Enrichment Design Biostatistics

Due to the growing interest in personalized medicine, where patients receive individually tailored therapies, the application of adaptive enrichment designs becomes increasingly more important.

In standard approaches, the confirmatory clinical trial is run in the full population and patients who are more likely to benefit are identified in post-hoc subgroup analyses. However, disregarding the heterogeneity in the treatment effect, can lead to an erroneous stop of the development, as the effect may be diluted by the low efficacy in the overall population. In situations with a prior confidence about a benefit, only in a subset of patients, a further option is to start the trial with a broad range of patients and to sequentially change inclusion criteria, based on the data of the ongoing trial. After pre-planned interim analyses, these so-called adaptive enrichment designs allow the further recruitment of only the targeted subgroup(s). Depending on the selection rule at the interim analyses, an early stop for futility is also possible. In case the first-stage data indicates a promising benefit only in the subgroup, the trial is enriched by allocating the remaining sample size only to this patient subset. If the interim data fulfills the selection criterion for all subgroups, the original study plan is maintained and the null hypotheses, regarding all subgroups, are tested at the final stage.

In research, it has been shown that adaptive enrichment designs can obtain higher power than fixed parallel group designs or adaptive designs without enrichment, when the same sample size is used. Hence, adaptive enrichment designs are a meaningful contribution in the context of precision medicine.

Data analysis, clinical biostatistics and more.

Staburo supports OncologyInformationService in Data Analytics

Staburo supports OncologyInformationService in Data Analytics

Staburo supports OncologyInformationService in Data Analytics 

Staburo recently started a successful collaboration with OncologyInformationService – O.I.s)! Staburo supports O.I.s) in the analysis of Real World Data in oncology.

O.I.s) has been providing an innovative, proprietary and tailor-made methodology and expertise in the field of Real World Data for oncology and hematology for over 20 years. O.I.s) supports the majority of specialized pharmaceutical companies in market access and market development across Europe. In addition, the company and its founder Lenka Kellermann, are members of several medical associations, such as the “Deutsche Krebsgesellschaft” (DKG), DGHO and ASCO, bringing together patients, physicians and researchers into an environment designed to improve the outcomes. We are looking forward to a great sustainable cooperation!

Data analysis, clinical biostatistics and more.